Primary systemic therapy of breast cancer

Oncologist

Volumn 11, Issue 6, 2006, Pages 574-589

  Sachelarie, Irina ^a   Grossbard, Michael L ^a   Chadha, Manjeet ^a   Feldman, Sheldon ^a   Ghesani, Munir ^a   Blum, Ronald H ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Anthracycline; Pathologic complete response; Primary systemic therapy; Taxane

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; PACLITAXEL; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; TAMOXIFEN; TAXOIDS;

EID: 33745670605     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-6-574     Document Type: Review

References (112)

1. Fisher B, Gunduz N, Coyle J et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001.
2. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
3. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
4. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
5. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96-102.
6. van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237.
7. Gianni L, Baselga L, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11: 8715-8721.
8. Gianni L, Baselga L, Eiermann W et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). Proc Am Soc Clin Oncol 2005;37a.
9. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
10. Scholl SM, Fourquet A, Asselain B et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-652.
11. Broet P, Sholl SM, de la Rochefordiere A et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58:151-156.
12. Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-1184.
13. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-194.
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
15. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686-3696.
16. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 2005;352:2302-2313.
17. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
18. Bear HD, Anderson S, Smith RE et al. A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. San Antonio Breast Cancer Symposium 2004, San Antonio, Texas, December 8-11, 2004.
19. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006;24:2019-2027.
20. Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(suppl 2):S69-S74.
21. Hutcheon AW, Heys SD, Sarkar TK et al. Neoadjuvant docetaxel in locally advanced breast cancer. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
22. von Minckwitz G, Blohmer JU, Loehr A et al. Comparison of docetaxel/ doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy -first results of the phase III GEPARTRIO-Study by the German Breast Group. San Antonio Breast Cancer Symposium 2005, San Antonio, Texas, December 8-12, 2005.
23. Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988-2995.
24. Gianni L, Zambetti M, Clark K et al. Gene expression profiles of paraffin embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 2004;23:501a.
25. Chang J, Powles TJ, Allred DC et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-3063.
26. Ellis P, Smith I, Ashley S et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998;16:107-114.
27. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10:6622-6628.
28. Ring AE, Smith IE, Ashley S et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91:2012-2017.
29. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype. San Antonio Breast Cancer Symposium 2004, San Antonio, Texas, December 8-11, 2004.
30. Rouzier R, Pusztai L, Delaloge S et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005;23:8331-8339.
31. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685.
32. Brain EG, Bachelot T, Serin D et al. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 2005;293:2367-2371.
33. Untch M, Konecny G, Ditsch N et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 2002;21:133a.
34. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
35. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004;23:512a.
36. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
37. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
38. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
39. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
40. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
41. Carey LA, Dees EC, Sawyer L et al. Response to trastuzumab given with paclitaxel immediately following 4AC as initial therapy for primary breast cancer. San Antonio Breast Cancer Symposium 2002, San Antonio, Texas, December 11-14, 2002.
42. Bines J, Murad A, Lago S et al. Weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer - a Brazilian multicenter study. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
43. Coudert B, Arnould L, Moreau L et al. Final pathological complete response of neoadjuvant trastuzumab and docetaxel chemotherapy in HER-2 positive (3+) localized breast cancer without possible primary conserving surgery. San Antonio Breast Cancer Symposium 2004, San Antonio, Texas, December 8-11, 2004.
44. Wenzel C, Hussian D, Bartsch R et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004;130:400-404.
45. Hurley J, Doliny P, De Zarraga F et al. Platinum salts and docetaxel as primary therapy of locally advanced and inflammatory breast cancer: the final report of three sequential studies. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
46. Limentani SA, Brufsky AM, Erban JK et al. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine, and trastuzumab with growth factor support. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
47. Harris L, Burstein HJ, Gelman R et al. Preoperative trastuzumab and vinorelbine is a highly active, well-tolerated regimen for HER2 3+/FISH+ stage II/III breast cancer. Proc Am Soc Clin Oncol 2003;22:86a.
48. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
49. Buzdar A, Valero V, Theriault R et al. Pathologic complete response to chemotherapy is related to hormone receptor status. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
50. Mauriac L, Debled M, Durand M et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 2002;13:293-298.
51. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
52. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine chemotherapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
53. Semiglazov VF, Ivanov VG, Ziltzova EK et al. The relative efficacy of neoadjuvant endocrine therapy versus chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 2004;23:519a.
54. Gil MJ, Barnadas A, Cirera L et al. Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial. Proc Am Soc Clin Oncol 2004;23:603a.
55. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
56. Mouridsen H, Chaudri-Ross HA. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. The Oncologist 2004;9:497-506.
57. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients - a randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004;23:515a.
58. Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
59. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
60. Thurlimann BJ, Keshaviah A, Mouridsen H et al. BIG 1-98: randomized double-blind phase III study to evaluate letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc Am Soc Clin Oncol 2005;24:511a.
61. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrazole, tamoxifen, or both in combination: the Immediate Preoperative Anastrazole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-5116.
62. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative "Arimidex" compared to Tamoxifen (PROACT) trial. Cancer 2006;106:2095-2103.
63. Semiglazov VF, Kletsel AE, Semiglazov VV et al. Exemestane versus tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER positive breast cancer (T2N1-2, T3N0-1, T4N0M0). Proc Am Soc Clin Oncol 2005;24:530a.
64. Hoff PM, Valero V, Buzdar AU et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000;88:2054-2060.
65. Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-420.
66. Arpino G, Bardou VJ, Clark GM et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-R156.
67. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-48.
68. Chaturvedi S, Heys SD, Chaturvedi RS et al. Primary chemotherapy to breast cancers. Does histological type matter? San Antonio Breast Cancer Symposium 2004, San Antonio, Texas, December 8-11, 2004.
69. Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998;339:941-946.
70. McMasters KM, Tuttle TM, Carlson DJ et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-2566.
71. Tafra L, Lannin DR, Swanson MS et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001;233:51-59.
72. Breslin TM, Cohen L, Sahin A et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-3486.
73. Nason KS, Anderson BO, Byrd DR et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-2194.
74. Julian TB, Patel N, Dusi D et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001;182:407-410.
75. Fernandez A, Cortes M, Benito E et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001;22:361-366.
76. Stearns V, Ewing CA, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-242.
77. Haid A, Tausch C, Lang A et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001;92:1080-1084.
78. Miller AR, Thomason VE, Yeh IT et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002;9:243-247.
79. Mamounas EP, Brown A, Anderson S et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-2702.
80. Lang JE, Esserman LJ, Ewing CA et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. Am Coll Surg 2004;199:856-862.
81. Shen J, Mirza NQ, Gilcrease M et al. Feasibility and accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients with cytologically proven axillary metastases. San Antonio Breast Cancer Symposium 2004, San Antonio, Texas, December 8-11, 2004.
82. Jones JL, Zabicki K, Christian RL et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 2005;190:517-520.
83. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 1999;6:109-116.
84. Weir L, Speers C, D'Yachkova Y et al. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002;20:1793-1799.
85. Zambetti M, Oriana S, Quattrone P et al. Combined sequential approach in locally advanced breast cancer. Ann Oncol 1999;10:305-310.
86. Singletary SE, Mc Neese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast cancer. Cancer 1992;69:2849-2852.
87. Kuske RR, Farr GH, Graham MLV et al. Can preoperative chemotherapy cause patients with advanced breast cancer to become eligible for breast conserving therapy? Breast Cancer Res Treat 1992;23:166.
88. Touboul E, Lefranc JP, Blondon J et al. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 1997;42:219-229.
89. Recht A, Gray R, Davidson NE et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:1689-1700.
90. Huang EH, Tucker SL, Strom EA et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691-4699.
91. Buchholz TA, Tucker SL, Masullo L et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002;20:17-23.
92. Graham MV, Perez CA, Kuske RR et al. Locally advanced (noninflammatory) carcinoma of the breast: results and comparisons of various treatment modalities. Int J Radiat Oncol Biol Phys 1991;21:311-318.
93. Hortobagyi GN, Ames FC, Buzdar AU et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-2516.
94. Uematsu M, Bornstein BA, Recht A et al. Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer. Int J Radiat Oncol Biol Phys 1993;25:765-770.
95. Helvie MA, Joynt LK, Cody RL et al. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996;198:327-332.
96. Wahl, RL, Zasadny K, Helvie M et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
97. Jansson T, Westlin JE, Ahlstrom H et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470-1477.
98. Bassa P, Kim EE, Inoue T et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-938.
99. 18F]- fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-1695.
100. Smith IC, Welch AE, Hutcheon AW et al. Positron emission tomography using [18F]- fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-1688.
101. Rousseau C, Ferrer L, Bridji B et al. Early response monitoring by FDG-PET to neoadjuvant chemotherapy in locally advanced breast cancer patients. Proc Am Soc Clin Oncol 2005;24:2022a.
102. Gennari A, Donati S, Salvadori B et al. Role of 2-[18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156-161; discussion 162-163.
103. Stafford SE, Gralow JR, Schubert EK et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002;9:913-921.
104. Mortimer JE, Dehdashti F, Siegel BA et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797-2803.
105. Londero V, Bazzocchi M, Del Frate C et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004;14:1371-1379.
106. Esserman L, Kaplan E, Partridge S et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001;8:549-559.
107. Wasser K, Klein SK, Fink C et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003;13:80-87.
108. Martincich L, Montemurro F, De Rosa G et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76.
109. Partridge SC, Gibbs JE, Lu Y et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrencefree survival. AJR Am J Roentgenol 2005;184:1774-1781.
110. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
111. Rouzier R, Extra JM, Klijanienko J et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304-1310.
112. Goldhirsch A, Gelber RD, Simes RJ et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989;7:36-44.